Welcome to our dedicated page for Catheter Precision SEC filings (Ticker: VTAK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Catheter Precision's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Catheter Precision's regulatory disclosures and financial reporting.
Catheter Precision, Inc. furnished a Current Report on Form 8-K to announce that it issued a press release on August 11, 2025 reporting its financial results for the three and six months ended June 30, 2025. The company states the full press release is attached as Exhibit 99.1 and is incorporated by reference into the report. The company also clarifies that the information furnished under Item 2.02, including Exhibit 99.1, is being furnished and not filed for purposes of Section 18 of the Exchange Act and will not be incorporated by reference into future SEC filings unless expressly stated.
Catheter Precision, Inc. (NYSE American: VTAK) is updating its at-the-market (ATM) program. The new prospectus supplement limits additional issuances to $1.53 million of common stock that may be sold through Ladenburg Thalmann.
Key figures:
- Shares already sold: 8,649,526 for gross proceeds of $2.73 million during the last 12 months.
- Current public float: 21,336,987 shares worth $12.8 million (calculated at $0.60, the highest close in the past 60 days).
- Form S-3 Rule I.B.6 cap: While float remains below $75 million, VTAK may sell only one-third of its float every 12 months; $1.53 million capacity remains after prior sales.
- Recent market price: $0.17 per share on 4 Aug 2025, far below the float-calculation price.
Should the float rise—or exceed $75 million—the company may expand the program and will file another supplement. Prospective investors are urged to review the incorporated “Risk Factors,” particularly potential dilution and price pressure from continued share sales.
Catheter Precision, Inc. (VTAK) filed an 8-K detailing annual-meeting results and a forthcoming reverse stock split.
Only 5.81 M of 12.59 M eligible shares (46.1%) were voted. Six proposals passed: (1) re-election of director Martin Colombatto (2.57 M for); (2) issuance of up to 4.29 M shares on Series L warrant exercise; (3) issuance of up to 8.57 M shares on Series B preferred conversion; (4) issuance of 0.26 M shares for placement-agent warrants; (5) authorization of a reverse split between 1-for-5 and 1-for-19; (6) ratification of WithumSmith+Brown as auditor (4.96 M for).
The board has chosen the maximum ratio, implementing a 1-for-19 reverse split effective 15 Aug 2025. Shares outstanding will be reduced from ~23.3 M to ~1.2 M; fractional shares will be paid in cash. Authorized capital (60 M common, 10 M preferred) is unchanged, and ownership percentages are unaffected apart from cash-settled fractions. The action seeks to restore compliance with the NYSE American’s minimum bid requirement. VTAK will continue trading under its ticker, adopting new CUSIP 74933X 708.
Catheter Precision, Inc. (VTAK) filed a Form S-8 on 26 June 2025 to register shares issuable under two employee equity programs: (1) the Catheter Precision 2023 Equity Incentive Plan and (2) a stand-alone stock-option grant dated 6 Jan 2025 to CFO Philip Anderson. The filing allows the Company to issue these shares to employees without additional SEC registration, thereby facilitating equity-based compensation.
Registrant profile: Delaware corporation, non-accelerated filer, smaller reporting company, principal offices in Fort Mill, SC. The registration statement incorporates by reference the Company’s 2024 Form 10-K (filed 31 Mar 2025, amended 30 Apr 2025), Q1-2025 Form 10-Q (filed 14 May 2025) and thirteen Form 8-Ks filed between 7 Jan and 13 Jun 2025. These filings collectively provide investors the requisite financial and operational background.
Legal & governance highlights: The document reiterates broad indemnification protections for directors and officers under Delaware law and the Company’s bylaws, including advancement of expenses. The SEC’s longstanding position that indemnification for Securities Act liabilities is unenforceable is also acknowledged.
Exhibits of note: (i) legal opinion on share legality (Ex. 5.1), (ii) auditor consent (Ex. 23.2), (iii) full 2023 Incentive Plan (Ex. 99.1) and the individual non-plan option award (Ex. 99.2). Exhibit 107 contains the fee table; specific share counts and aggregate offering value are not provided in the excerpt.
Investor impact: Because S-8 registrations are routine administrative matters with no immediate cash proceeds, the filing is operationally neutral. Over time, however, issuances under the plan will increase the fully diluted share count and may introduce incremental dilution.